img

Global Short-acting B2 Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Short-acting B2 Agonists Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema.
Short-acting B2 Agonists report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Short-acting B2 Agonists market is projected to reach US$ 5919 million in 2029, increasing from US$ 4791 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2029. Demand from COPD and Asthma are the major drivers for the industry.
The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Short-acting B2 Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bayer AG
Teva
Roche
Viatris
GSK
Cipla Limited
Johnson & Johnson
Merck
Segment by Type
Albuterol
Metaproterenol
Levalbuterol
Other

Segment by Application


COPD
Asthma
Other

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Short-acting B2 Agonists market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Short-acting B2 Agonists, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Short-acting B2 Agonists industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Short-acting B2 Agonists in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Short-acting B2 Agonists introduction, etc. Short-acting B2 Agonists Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Short-acting B2 Agonists market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Short-acting B2 Agonists Market Overview
1.1 Short-acting B2 Agonists Product Overview
1.2 Short-acting B2 Agonists Market Segment by Type
1.2.1 Albuterol
1.2.2 Metaproterenol
1.2.3 Levalbuterol
1.2.4 Other
1.3 Global Short-acting B2 Agonists Market Size by Type
1.3.1 Global Short-acting B2 Agonists Market Size Overview by Type (2018-2029)
1.3.2 Global Short-acting B2 Agonists Historic Market Size Review by Type (2018-2024)
1.3.3 Global Short-acting B2 Agonists Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Short-acting B2 Agonists Sales Breakdown by Type (2018-2024)
1.4.2 Europe Short-acting B2 Agonists Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Short-acting B2 Agonists Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Short-acting B2 Agonists Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Short-acting B2 Agonists Sales Breakdown by Type (2018-2024)
2 Global Short-acting B2 Agonists Market Competition by Company
2.1 Global Top Players by Short-acting B2 Agonists Sales (2018-2024)
2.2 Global Top Players by Short-acting B2 Agonists Revenue (2018-2024)
2.3 Global Top Players by Short-acting B2 Agonists Price (2018-2024)
2.4 Global Top Manufacturers Short-acting B2 Agonists Manufacturing Base Distribution, Sales Area, Product Type
2.5 Short-acting B2 Agonists Market Competitive Situation and Trends
2.5.1 Short-acting B2 Agonists Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Short-acting B2 Agonists Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Short-acting B2 Agonists as of 2022)
2.7 Date of Key Manufacturers Enter into Short-acting B2 Agonists Market
2.8 Key Manufacturers Short-acting B2 Agonists Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Short-acting B2 Agonists Status and Outlook by Region
3.1 Global Short-acting B2 Agonists Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Short-acting B2 Agonists Historic Market Size by Region
3.2.1 Global Short-acting B2 Agonists Sales in Volume by Region (2018-2024)
3.2.2 Global Short-acting B2 Agonists Sales in Value by Region (2018-2024)
3.2.3 Global Short-acting B2 Agonists Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Short-acting B2 Agonists Forecasted Market Size by Region
3.3.1 Global Short-acting B2 Agonists Sales in Volume by Region (2024-2029)
3.3.2 Global Short-acting B2 Agonists Sales in Value by Region (2024-2029)
3.3.3 Global Short-acting B2 Agonists Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Short-acting B2 Agonists by Application
4.1 Short-acting B2 Agonists Market Segment by Application
4.1.1 COPD
4.1.2 Asthma
4.1.3 Other
4.2 Global Short-acting B2 Agonists Market Size by Application
4.2.1 Global Short-acting B2 Agonists Market Size Overview by Application (2018-2029)
4.2.2 Global Short-acting B2 Agonists Historic Market Size Review by Application (2018-2024)
4.2.3 Global Short-acting B2 Agonists Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Short-acting B2 Agonists Sales Breakdown by Application (2018-2024)
4.3.2 Europe Short-acting B2 Agonists Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Short-acting B2 Agonists Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Short-acting B2 Agonists Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Short-acting B2 Agonists Sales Breakdown by Application (2018-2024)
5 North America Short-acting B2 Agonists by Country
5.1 North America Short-acting B2 Agonists Historic Market Size by Country
5.1.1 North America Short-acting B2 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Short-acting B2 Agonists Sales in Volume by Country (2018-2024)
5.1.3 North America Short-acting B2 Agonists Sales in Value by Country (2018-2024)
5.2 North America Short-acting B2 Agonists Forecasted Market Size by Country
5.2.1 North America Short-acting B2 Agonists Sales in Volume by Country (2024-2029)
5.2.2 North America Short-acting B2 Agonists Sales in Value by Country (2024-2029)
6 Europe Short-acting B2 Agonists by Country
6.1 Europe Short-acting B2 Agonists Historic Market Size by Country
6.1.1 Europe Short-acting B2 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Short-acting B2 Agonists Sales in Volume by Country (2018-2024)
6.1.3 Europe Short-acting B2 Agonists Sales in Value by Country (2018-2024)
6.2 Europe Short-acting B2 Agonists Forecasted Market Size by Country
6.2.1 Europe Short-acting B2 Agonists Sales in Volume by Country (2024-2029)
6.2.2 Europe Short-acting B2 Agonists Sales in Value by Country (2024-2029)
7 Asia-Pacific Short-acting B2 Agonists by Region
7.1 Asia-Pacific Short-acting B2 Agonists Historic Market Size by Region
7.1.1 Asia-Pacific Short-acting B2 Agonists Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Short-acting B2 Agonists Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Short-acting B2 Agonists Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Short-acting B2 Agonists Forecasted Market Size by Region
7.2.1 Asia-Pacific Short-acting B2 Agonists Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Short-acting B2 Agonists Sales in Value by Region (2024-2029)
8 Latin America Short-acting B2 Agonists by Country
8.1 Latin America Short-acting B2 Agonists Historic Market Size by Country
8.1.1 Latin America Short-acting B2 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Short-acting B2 Agonists Sales in Volume by Country (2018-2024)
8.1.3 Latin America Short-acting B2 Agonists Sales in Value by Country (2018-2024)
8.2 Latin America Short-acting B2 Agonists Forecasted Market Size by Country
8.2.1 Latin America Short-acting B2 Agonists Sales in Volume by Country (2024-2029)
8.2.2 Latin America Short-acting B2 Agonists Sales in Value by Country (2024-2029)
9 Middle East and Africa Short-acting B2 Agonists by Country
9.1 Middle East and Africa Short-acting B2 Agonists Historic Market Size by Country
9.1.1 Middle East and Africa Short-acting B2 Agonists Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Short-acting B2 Agonists Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Short-acting B2 Agonists Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Short-acting B2 Agonists Forecasted Market Size by Country
9.2.1 Middle East and Africa Short-acting B2 Agonists Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Short-acting B2 Agonists Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bayer AG
10.1.1 Bayer AG Company Information
10.1.2 Bayer AG Introduction and Business Overview
10.1.3 Bayer AG Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Bayer AG Short-acting B2 Agonists Products Offered
10.1.5 Bayer AG Recent Development
10.2 Teva
10.2.1 Teva Company Information
10.2.2 Teva Introduction and Business Overview
10.2.3 Teva Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Teva Short-acting B2 Agonists Products Offered
10.2.5 Teva Recent Development
10.3 Roche
10.3.1 Roche Company Information
10.3.2 Roche Introduction and Business Overview
10.3.3 Roche Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Roche Short-acting B2 Agonists Products Offered
10.3.5 Roche Recent Development
10.4 Viatris
10.4.1 Viatris Company Information
10.4.2 Viatris Introduction and Business Overview
10.4.3 Viatris Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Viatris Short-acting B2 Agonists Products Offered
10.4.5 Viatris Recent Development
10.5 GSK
10.5.1 GSK Company Information
10.5.2 GSK Introduction and Business Overview
10.5.3 GSK Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.5.4 GSK Short-acting B2 Agonists Products Offered
10.5.5 GSK Recent Development
10.6 Cipla Limited
10.6.1 Cipla Limited Company Information
10.6.2 Cipla Limited Introduction and Business Overview
10.6.3 Cipla Limited Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Cipla Limited Short-acting B2 Agonists Products Offered
10.6.5 Cipla Limited Recent Development
10.7 Johnson & Johnson
10.7.1 Johnson & Johnson Company Information
10.7.2 Johnson & Johnson Introduction and Business Overview
10.7.3 Johnson & Johnson Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Johnson & Johnson Short-acting B2 Agonists Products Offered
10.7.5 Johnson & Johnson Recent Development
10.8 Merck
10.8.1 Merck Company Information
10.8.2 Merck Introduction and Business Overview
10.8.3 Merck Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Merck Short-acting B2 Agonists Products Offered
10.8.5 Merck Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Short-acting B2 Agonists Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Short-acting B2 Agonists Industrial Chain Analysis
11.4 Short-acting B2 Agonists Market Dynamics
11.4.1 Short-acting B2 Agonists Industry Trends
11.4.2 Short-acting B2 Agonists Market Drivers
11.4.3 Short-acting B2 Agonists Market Challenges
11.4.4 Short-acting B2 Agonists Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Short-acting B2 Agonists Distributors
12.3 Short-acting B2 Agonists Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Albuterol
Table 2. Major Company of Metaproterenol
Table 3. Major Company of Levalbuterol
Table 4. Major Company of Other
Table 5. Global Short-acting B2 Agonists Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Short-acting B2 Agonists Sales by Type (2018-2024) & (K Units)
Table 7. Global Short-acting B2 Agonists Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Short-acting B2 Agonists Sales by Type (2018-2024) & (US& Million)
Table 9. Global Short-acting B2 Agonists Market Share in Value by Type (2018-2024)
Table 10. Global Short-acting B2 Agonists Price by Type (2018-2024) & (US$/Unit)
Table 11. Global Short-acting B2 Agonists Sales by Type (2024-2029) & (K Units)
Table 12. Global Short-acting B2 Agonists Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Short-acting B2 Agonists Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Short-acting B2 Agonists Sales Market Share in Value by Type (2024-2029)
Table 15. Global Short-acting B2 Agonists Price by Type (2024-2029) & (US$/Unit)
Table 16. North America Short-acting B2 Agonists Sales by Type (2018-2024) & (K Units)
Table 17. North America Short-acting B2 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Short-acting B2 Agonists Sales (K Units) by Type (2018-2024)
Table 19. Europe Short-acting B2 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Short-acting B2 Agonists Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific Short-acting B2 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Short-acting B2 Agonists Sales (K Units) by Type (2018-2024)
Table 23. Latin America Short-acting B2 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Short-acting B2 Agonists Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa Short-acting B2 Agonists Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Short-acting B2 Agonists Sales by Company (2018-2024) & (K Units)
Table 27. Global Short-acting B2 Agonists Sales Share by Company (2018-2024)
Table 28. Global Short-acting B2 Agonists Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Short-acting B2 Agonists Revenue Share by Company (2018-2024)
Table 30. Global Market Short-acting B2 Agonists Price by Company (2018-2024) & (US$/Unit)
Table 31. Global Short-acting B2 Agonists Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Short-acting B2 Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Short-acting B2 Agonists as of 2022)
Table 34. Date of Key Manufacturers Enter into Short-acting B2 Agonists Market
Table 35. Key Manufacturers Short-acting B2 Agonists Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Short-acting B2 Agonists Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Short-acting B2 Agonists Sales by Region (2018-2024) & (K Units)
Table 39. Global Short-acting B2 Agonists Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Short-acting B2 Agonists Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Short-acting B2 Agonists Sales Market Share in Value by Region (2018-2024)
Table 42. Global Short-acting B2 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 43. Global Short-acting B2 Agonists Sales by Region (2024-2029) & (K Units)
Table 44. Global Short-acting B2 Agonists Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Short-acting B2 Agonists Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Short-acting B2 Agonists Sales Market Share in Value by Region (2024-2029)
Table 47. Global Short-acting B2 Agonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 48. Global Short-acting B2 Agonists Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Short-acting B2 Agonists Sales by Application (2018-2024) & (K Units)
Table 50. Global Short-acting B2 Agonists Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Short-acting B2 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Short-acting B2 Agonists Sales Market Share in Value by Application (2018-2024)
Table 53. Global Short-acting B2 Agonists Price by Application (2018-2024) & (US$/Unit)
Table 54. Global Short-acting B2 Agonists Sales by Application (2024-2029) & (K Units)
Table 55. Global Short-acting B2 Agonists Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Short-acting B2 Agonists Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Short-acting B2 Agonists Sales Market Share in Value by Application (2024-2029)
Table 58. Global Short-acting B2 Agonists Price by Application (2024-2029) & (US$/Unit)
Table 59. North America Short-acting B2 Agonists Sales by Application (2018-2024) (K Units)
Table 60. North America Short-acting B2 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Short-acting B2 Agonists Sales by Application (2018-2024) (K Units)
Table 62. Europe Short-acting B2 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Short-acting B2 Agonists Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific Short-acting B2 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Short-acting B2 Agonists Sales by Application (2018-2024) (K Units)
Table 66. Latin America Short-acting B2 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Short-acting B2 Agonists Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa Short-acting B2 Agonists Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Short-acting B2 Agonists Sales by Country (2018-2024) & (K Units)
Table 70. North America Short-acting B2 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Short-acting B2 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Short-acting B2 Agonists Sales Market Share in Value by Country (2018-2024)
Table 73. North America Short-acting B2 Agonists Sales by Country (2024-2029) & (K Units)
Table 74. North America Short-acting B2 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Short-acting B2 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Short-acting B2 Agonists Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Short-acting B2 Agonists Sales by Country (2018-2024) & (K Units)
Table 78. Europe Short-acting B2 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Short-acting B2 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Short-acting B2 Agonists Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Short-acting B2 Agonists Sales by Country (2024-2029) & (K Units)
Table 82. Europe Short-acting B2 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Short-acting B2 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Short-acting B2 Agonists Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Short-acting B2 Agonists Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Short-acting B2 Agonists Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Short-acting B2 Agonists Sales by Region (2024-2029) & (K Units)
Table 90. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Short-acting B2 Agonists Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Short-acting B2 Agonists Sales by Country (2018-2024) & (K Units)
Table 94. Latin America Short-acting B2 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Short-acting B2 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Short-acting B2 Agonists Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Short-acting B2 Agonists Sales by Country (2024-2029) & (K Units)
Table 98. Latin America Short-acting B2 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Short-acting B2 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Short-acting B2 Agonists Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Short-acting B2 Agonists Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Short-acting B2 Agonists Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Short-acting B2 Agonists Sales by Country (2024-2029) & (K Units)
Table 106. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Short-acting B2 Agonists Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Value by Country (2024-2029)
Table 109. Bayer AG Company Information
Table 110. Bayer AG Introduction and Business Overview
Table 111. Bayer AG Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Bayer AG Short-acting B2 Agonists Product
Table 113. Bayer AG Recent Development
Table 114. Teva Company Information
Table 115. Teva Introduction and Business Overview
Table 116. Teva Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Teva Short-acting B2 Agonists Product
Table 118. Teva Recent Development
Table 119. Roche Company Information
Table 120. Roche Introduction and Business Overview
Table 121. Roche Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Roche Short-acting B2 Agonists Product
Table 123. Roche Recent Development
Table 124. Viatris Company Information
Table 125. Viatris Introduction and Business Overview
Table 126. Viatris Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Viatris Short-acting B2 Agonists Product
Table 128. Viatris Recent Development
Table 129. GSK Company Information
Table 130. GSK Introduction and Business Overview
Table 131. GSK Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. GSK Short-acting B2 Agonists Product
Table 133. GSK Recent Development
Table 134. Cipla Limited Company Information
Table 135. Cipla Limited Introduction and Business Overview
Table 136. Cipla Limited Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Cipla Limited Short-acting B2 Agonists Product
Table 138. Cipla Limited Recent Development
Table 139. Johnson & Johnson Company Information
Table 140. Johnson & Johnson Introduction and Business Overview
Table 141. Johnson & Johnson Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Johnson & Johnson Short-acting B2 Agonists Product
Table 143. Johnson & Johnson Recent Development
Table 144. Merck Company Information
Table 145. Merck Introduction and Business Overview
Table 146. Merck Short-acting B2 Agonists Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. Merck Short-acting B2 Agonists Product
Table 148. Merck Recent Development
Table 149. Key Raw Materials Lists
Table 150. Raw Materials Key Suppliers Lists
Table 151. Short-acting B2 Agonists Market Trends
Table 152. Short-acting B2 Agonists Market Drivers
Table 153. Short-acting B2 Agonists Market Challenges
Table 154. Short-acting B2 Agonists Market Restraints
Table 155. Short-acting B2 Agonists Distributors List
Table 156. Short-acting B2 Agonists Downstream Customers
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Short-acting B2 Agonists Product Picture
Figure 2. Global Short-acting B2 Agonists Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Short-acting B2 Agonists Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Short-acting B2 Agonists Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Albuterol
Figure 6. Global Albuterol Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Metaproterenol
Figure 8. Global Metaproterenol Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Levalbuterol
Figure 10. Global Levalbuterol Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Other
Figure 12. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Global Short-acting B2 Agonists Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Short-acting B2 Agonists Sales Market Share by Type in 2022 & 2029
Figure 15. North America Short-acting B2 Agonists Sales Market Share in Volume by Type in 2022
Figure 16. North America Short-acting B2 Agonists Sales Market Share in Value by Type in 2022
Figure 17. Europe Short-acting B2 Agonists Sales Market Share in Volume by Type in 2022
Figure 18. Europe Short-acting B2 Agonists Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Value by Type in 2022
Figure 21. Latin America Short-acting B2 Agonists Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Short-acting B2 Agonists Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Short-acting B2 Agonists Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Short-acting B2 Agonists Revenue in 2022
Figure 27. Short-acting B2 Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of COPD
Figure 29. Global COPD Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Asthma
Figure 31. Global Asthma Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Other
Figure 33. Global Other Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Global Short-acting B2 Agonists Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Short-acting B2 Agonists Sales Market Share by Application in 2022 & 2029
Figure 36. North America Short-acting B2 Agonists Sales Market Share in Volume by Application in 2022
Figure 37. North America Short-acting B2 Agonists Sales Market Share in Value by Application in 2022
Figure 38. Europe Short-acting B2 Agonists Sales Market Share in Volume by Application in 2022
Figure 39. Europe Short-acting B2 Agonists Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Short-acting B2 Agonists Sales Market Share in Value by Application in 2022
Figure 42. Latin America Short-acting B2 Agonists Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Short-acting B2 Agonists Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Short-acting B2 Agonists Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Short-acting B2 Agonists Manufacturing Cost Structure
Figure 47. Short-acting B2 Agonists Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries